share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K：重大事件
美股sec公告 ·  03/29 14:43
Moomoo AI 已提取核心信息
Avenue Therapeutics, Inc. reported on March 29, 2024, that it has received a delisting notice from Nasdaq due to the company's failure to maintain the minimum bid price requirement. The company's common stock had been trading below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Although a 180-day grace period ending March 25, 2024, was granted to regain compliance, Avenue Therapeutics was unable to meet the requirement. Despite the delisting determination issued on March 26, 2024, the company's listing status remains unaffected for now, following a decision by the Nasdaq Hearings Panel on March 11, 2024, which granted an extension until May 20, 2024, for the company to demonstrate compliance with the minimum stockholders’ equity and bid price rules. Avenue Therapeutics is exploring all available options to regain compliance, but there is no guarantee of success.
Avenue Therapeutics, Inc. reported on March 29, 2024, that it has received a delisting notice from Nasdaq due to the company's failure to maintain the minimum bid price requirement. The company's common stock had been trading below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Although a 180-day grace period ending March 25, 2024, was granted to regain compliance, Avenue Therapeutics was unable to meet the requirement. Despite the delisting determination issued on March 26, 2024, the company's listing status remains unaffected for now, following a decision by the Nasdaq Hearings Panel on March 11, 2024, which granted an extension until May 20, 2024, for the company to demonstrate compliance with the minimum stockholders’ equity and bid price rules. Avenue Therapeutics is exploring all available options to regain compliance, but there is no guarantee of success.
Avenue Therapeutics, Inc.于2024年3月29日报告称，由于该公司未能维持最低出价要求，它已收到纳斯达克的退市通知。该公司的普通股连续30个工作日交易价格低于每股1.00美元，违反了纳斯达克上市规则5550（a）（2）。尽管批准了截至2024年3月25日的180天宽限期以恢复合规，但Avenue Therapeutics仍无法满足这一要求。尽管2024年3月26日发布了退市决定，但该公司的上市状况目前仍未受到影响，此前纳斯达克听证会小组于2024年3月11日作出决定，批准将公司证明遵守最低股东权益和出价规则的期限延长至2024年5月20日。Avenue Therapeutics正在探索所有可用的选择以恢复合规性，但无法保证成功。
Avenue Therapeutics, Inc.于2024年3月29日报告称，由于该公司未能维持最低出价要求，它已收到纳斯达克的退市通知。该公司的普通股连续30个工作日交易价格低于每股1.00美元，违反了纳斯达克上市规则5550（a）（2）。尽管批准了截至2024年3月25日的180天宽限期以恢复合规，但Avenue Therapeutics仍无法满足这一要求。尽管2024年3月26日发布了退市决定，但该公司的上市状况目前仍未受到影响，此前纳斯达克听证会小组于2024年3月11日作出决定，批准将公司证明遵守最低股东权益和出价规则的期限延长至2024年5月20日。Avenue Therapeutics正在探索所有可用的选择以恢复合规性，但无法保证成功。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息